Immugenia is proud to have been selected to participate on February 22, 2024 at the Johnson & Johnson Inaugural Gene Therapy Summit in San Francisco! We were selected to showcase our technology to the west coast community of gene therapy development.

The Canadian Cancer Society, CQDM, the Cole Foundation and Oncopole grant close to $8.5 million to four researchers in Quebec to support pediatric cancer research

Immugenia Obtains Pre-Seed Funding from adMare BioInnovations, ACET Capital, and Sherbrooke Innopole to Develop a Cancer Treatment Which Would Prevent Relapses